Finoriq research workspace
ACADIA PHARMACEUTICALS INC (ACAD) SEC Filings & Filing Highlights
ACADIA PHARMACEUTICALS INC offers NUPLAZID (pimavanserin), a selective serotonin inverse. Review ACAD SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
- Company
- ACADIA PHARMACEUTICALS INC (ACAD)
- Ticker
- ACAD
- Market Cap
- $4.3B
- Latest Price
- $25.22
- Industry
- Biotech & Pharma
ACADIA PHARMACEUTICALS INC (ACAD) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ACADIA PHARMACEUTICALS INC (ACAD).
| Event | Form | Date |
|---|---|---|
| The Company held its Annual Meeting on May 29, 2026The Company held its Annual Meeting on May 29, 2026 | 8-K5.07 | 2026-05-29 |
| (e) On May 29, 2026, Acadia Pharmaceuticals Inc. (the “Company”) held its 2026 Annual Meeting o...(e) On May 29, 2026, Acadia Pharmaceuticals Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As fu... | 8-K5.02 | 2026-05-29 |
| Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financia...Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance | 8-K2.02 | 2026-05-06 |
| Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.,...Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following... | 8-K7.01 | 2026-05-01 |
| On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed A...On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) o... | 8-K5.02 | 2026-05-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.